Bone Drugs in Pediatrics

1. Front Matter

   Pages i-xiii

   PDF

2. Introduction

   • Gordon L. Klein

   Pages 1-3

3. Developmental Pharmacokinetics: Drug Disposition Relative to Age

   • Michael D. Reed, Michelle L. Bestic

   Pages 5-22

4. Drug Development for Pediatric Diseases with Bone Loss

   • Chi Zhang

   Pages 23-36

5. Paediatric Bone Physiology and Monitoring the Safety and Efficacy of Bone Drugs in Children

   • John G. Logan, J. H. Duncan Bassett, Moira S. Cheung

   Pages 37-65

6. Bisphosphonates in Osteogenesis Imperfecta

   • Andrew Biggin, Craig F. Munns

   Pages 67-80

7. Use of Bisphosphonates in Genetic Diseases Other than Osteogenesis Imperfecta

   • Maria Luisa Bianchi

   Pages 81-99

8. Bisphosphonates in Pediatric Burn Injury

   • Gordon L. Klein

   Pages 101-115

9. Growth Hormone and Bone

   • Daisuke Harada, Yoshiki Seino

   Pages 117-134

10. Growth Hormone and Oxandrolone in Burned Children

    • Nigel Tapiwa Mabvuure, Alexis N. Thomas, Linda E. Sousse

    Pages 135-152

11. Pediatric Bone Drugs: Calcium and Vitamin D

    • Melissa S. Putman, Catherine M. Gordon

    Pages 153-181

12. Pediatric Maxillofacial Conditions and Drugs

    • Srinivas M. Susarla, Christina M. Jacobsen, Shelly Abramowicz

    Pages 183-198

13. Newer Adult Bone Drugs

    • Natalie E. Cusano, Aline G. Costa, Barbara C. Silva, John P. Bilezekian

    Pages 199-221

14. Conclusion: Whither (or Wither?) the Pharmacology of Pediatric Bone?

    • Gordon L. Klein

    Pages 223-224

15. Back Matter

    Pages 225-233

    PDF

Bone Drugs in Pediatrics brings together in one place the evidence for the use of certain drugs in the treatment and prevention of bone loss in children, as well as the reservations still present in the pediatric community regarding their use. Beginning with a discussion of developmental pharmacokinetics and drug development for pediatric diseases where bone loss occurs, such as osteogenesis imperfecta, the physiology of pediatric bone and how best to monitor the safety and efficacy of these drugs is presented. The pros and cons of utilizing the drugs themselves – such as bisphosphonates, antiresorptives and anabolic agents – within the pediatric population are carefully considered, with an eye toward safe and effective integration. The potential use of drugs in future treatment is also highlighted. On the whole, Bone Drugs in Pediatrics is a cogent presentation of the ongoing debate surrounding the potential for pharmacological interventions in pediatric bone loss.

• Anti-resorptive
• Bisphosphonate
• Growth hormone
• Oxandralone
• Pediatric bone drugs
• Pediatric bone loss
• Pediatric pharmacology

• Department of Orthopaedic Surgery, University of Texas Medical Branch, Galveston, USA

  Gordon L. Klein

Gordon L. Klein, MD, MPH, Department of Orthopaedic Surgery, University of Texas Medical Branch, Galveston, TX, USA.

Policies and ethics